title: Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India.
abstract: BACKGROUND
  Use of neoadjuvant chemotherapy (NACT) in locally advanced breast cancer (LABC) enables tumor reduction and conservative surgery. It is proposed in some studies that there may be an alteration in the hormonal receptor (HR) status and human epidermal growth factor receptor 2 (Her-2)/neu immune-expression following NACT.
  
  
  OBJECTIVE
  To study the status of estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu receptor before and after NACT in LABC.
  
  
  METHODS
  HR and Her-2/neu status were evaluated by immunohistochemistry on 100 core needle biopsy of primary tumors and surgical specimens after receiving NACT (NACT group); fifty patients without NACT served as non-NACT group, and discordance was compared between the two groups.
  
  
  RESULTS
  In the NACT group, discordance of 17%, 13%, and 11% was noted in ER, PR, and Her-2/neu status, while in non-NACT group, discordance seen in ER, PR, and Her-2/neu was 8%, 8%, and 4%, respectively.
  
  
  CONCLUSIONS
  There was a significant alteration in ER and Her-2/neu status from the core biopsy to the treated resected tumor in the study group. As these changes may impact treatment, HR and Her-2/neu expression reanalysis in final surgical specimens is recommended.
authors.affiliation: Department of Pathology, All Institute of Medical Sciences, New Delhi, India.
authors.forename: P
authors.initials: P
authors.lastname: Ramteke
authors.affiliation: Department of Surgery, All Institute of Medical Sciences, New Delhi, India.
authors.forename: V
authors.initials: V
authors.lastname: Seenu
authors.affiliation: Department of Surgery, All Institute of Medical Sciences, New Delhi, India.
authors.forename: R
authors.initials: R
authors.lastname: Prashad
authors.affiliation: Department of Pathology, All Institute of Medical Sciences, New Delhi, India.
authors.forename: S D
authors.initials: SD
authors.lastname: Gupta
authors.affiliation: Department of Pathology, All Institute of Medical Sciences, New Delhi, India.
authors.forename: V
authors.initials: V
authors.lastname: Iyer
authors.affiliation: Department of Surgical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All Institute of Medical Sciences, New Delhi, India.
authors.forename: Svs
authors.initials: S
authors.lastname: Deo
authors.affiliation: Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All Institute of Medical Sciences, New Delhi, India.
authors.forename: A
authors.initials: A
authors.lastname: Gogia
authors.affiliation: Department of Pathology, All Institute of Medical Sciences, New Delhi, India.
authors.forename: S
authors.initials: S
authors.lastname: Mathur
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000627:therapeutic use*; D006801:Humans; D007194:India; D008137:Longitudinal Studies; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D062606:Tertiary Care Centers
chemical_list: D012739:Gonadal Steroid Hormones; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human